Going beyond the ordinary to the extraordinary
Hinge Bio’s GEM-DIMER™ platform is creating a revolutionary class of therapeutics
Multivalent, multispecific antibody-based molecules that project freely into multidimensional space and cooperatively bind their disease target(s), enabling entirely new functionality for superior safety and efficacy.
Hinge Bio’s technology is broadly applicable across many diseases. Hinge Bio is initially focusing on developing products for infectious disease and cancer. Its lead infectious disease candidate, COVICEPT™, is in late preclinical development headed for an IND filing in 2022, and the first of its cancer candidates is expected to follow thereafter.
COVICEPT represents an entirely new approach to the treatment of COVID-19 by using Hinge Bio’s revolutionary technology to combine the broad therapeutic activity of the ACE2 receptor with a broadly neutralizing anti-COVID-19 antibody. The ACE2 and antibody portions of COVICEPT target distinct regions of the SARS-CoV-2 spike protein working together to achieve a level of synergy and effectiveness against diverse viral variants. Hinge Bio expects this approach to be broadly applicable to a number of viral diseases.
Hinge Bio is applying a similar approach in designing cancer therapeutics with enhanced functionality compared to existing product candidates. The multivalent, multispecific, multidimensional approach Hinge Bio is taking incorporates antibody and other protein domains that direct tumor targeting, T and NK effector cell engagement, effector cell activation, and domains which are expected to localize activity to the tumor microenvironment. To date, existing antibody technologies are typically limited in the number and types of domains that can be mobilized against cancer.
Hinge Bio’s platform is protected by numerous issued patents and patent applications with broad claims covering novel compositions of matter and methods for their synthesis and use.